Abbreviations used in the protocol are listed in Supplementary Table 1.
1. Preparation of solutions and buffers
NOTE: The commercial details of all the reagents are listed in the Table of Materials.
<ol>
	<li>Prepare 0.1 M Tris-HCl, pH 8.0 solution by adding 1 mL of 1 M Tris-HCl, pH 8.0 into 9 mL of deionized water in a glass vial, and mix well by vortexing. Store at 4 &#176;C for up to 3 months.</li>
	<li>Prepare...

Enrichment of Host Cell Proteins in Monoclonal Antibody Drug Products

<ol>
	<li>Aboulaich, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+novel+approach+to+monitor+clearance+of+host+cell+proteins+associated+with+monoclonal+antibodies.">A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies.</a> Biotechnology Progress. 30 (5), 1114-1124 (2014).</li><li>Goey, C. H., Alhuthali, S., Kontoravdi, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Host+cell+protein+removal+from+biopharmaceutical+preparations:+Towards+the+implementation+of+quality+by+design.">Host cell protein removal from biopharmaceutical preparations: Towards the implementation of quality by design.</a> Biotechnology Advances. 36 (4), 1223-1237 (2018).</li><li>Levy, N. E., Valente, K. N., Choe, L. H., Lee, K. H., Lenhoff, A. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+and+characterization+of+host+cell+protein+product-associated+impurities+in+monoclonal+antibody+bioprocessing.">Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing.</a> Biotechnology and Bioengineering. 111 (5), 904-912 (2014).</li><li>Molden, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Host+cell+protein+profiling+of+commercial+therapeutic+protein+drugs+as+a+benchmark+for+monoclonal+antibody-based+therapeutic+protein+development.">Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development.</a> MAbs. 13 (1), 1955811 (2021).</li><li>Bee, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Trace+levels+of+the+CHO+host+cell+protease+cathepsin+D+caused+particle+formation+in+a+monoclonal+antibody+product.">Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product.</a> Biotechnology Progress. 31 (5), 1360-1369 (2015).</li><li>Bracewell, D. G., Francis, R., Smales, C. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+future+of+host+cell+protein+(HCP)+identification+during+process+development+and+manufacturing+linked+to+a+risk-based+management+for+their+control.">The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control.</a> Biotechnology and Bioengineering. 112 (9), 1727-1737 (2015).</li><li>Chiu, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Knockout+of+a+difficult-to-remove+CHO+host+cell+protein,+lipoprotein+lipase,+for+improved+polysorbate+stability+in+monoclonal+antibody+formulations.">Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations.</a> Biotechnology and Bioengineering. 114 (5), 1006-1015 (2017).</li><li>Gilgunn, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+and+tracking+of+problematic+host+cell+proteins+removed+by+a+synthetic,+highly+functionalized+nonwoven+media+in+downstream+bioprocessing+of+monoclonal+antibodies.">Identification and tracking of problematic host cell proteins removed by a synthetic, highly functionalized nonwoven media in downstream bioprocessing of monoclonal antibodies.</a> Journal of Chromatography A. 1595, 28-38 (2019).</li><li>Graf, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+and+characterization+of+polysorbate-degrading+enzymes+in+a+monoclonal+antibody+formulation.">Identification and characterization of polysorbate-degrading enzymes in a monoclonal antibody formulation.</a> Journal of Pharmaceutical Sciences. 110 (11), 3558-3567 (2021).</li><li>Hall, T., Sandefur, S. L., Frye, C. C., Tuley, T. L., Huang, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Polysorbates+20+and+80+degradation+by+group+XV+lysosomal+phospholipase+A2+isomer+X1+in+monoclonal+antibody+formulations.">Polysorbates 20 and 80 degradation by group XV lysosomal phospholipase A2 isomer X1 in monoclonal antibody formulations.</a> Journal of Pharmaceutical Sciences. 105 (5), 1633-1642 (2016).</li><li>Jones, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=34;High-risk&amp;#34;+host+cell+proteins+(HCPs):+A+multi-company+collaborative+view.">34;High-risk&amp;#34; host cell proteins (HCPs): A multi-company collaborative view.</a> Biotechnology and Bioengineering. 118 (8), 2870-2885 (2021).</li><li>Li, X., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+and+characterization+of+a+residual+host+cell+protein+hexosaminidase+B+associated+with+N-glycan+degradation+during+the+stability+study+of+a+therapeutic+recombinant+monoclonal+antibody+product.">Identification and characterization of a residual host cell protein hexosaminidase B associated with N-glycan degradation during the stability study of a therapeutic recombinant monoclonal antibody product.</a> Biotechnology Progress. 37 (3), e3128 (2021).</li><li>Zhang, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Identification+of+the+specific+causes+of+polysorbate+20+degradation+in+monoclonal+antibody+formulations+containing+multiple+lipases.">Identification of the specific causes of polysorbate 20 degradation in monoclonal antibody formulations containing multiple lipases.</a> Pharmaceutical Research. 39 (1), 75-87 (2022).</li><li>Zhang, S., Xiao, H., Li, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Degradation+of+polysorbate+20+by+Sialate+O-Acetylesterase+in+monoclonal+antibody+formulations.">Degradation of polysorbate 20 by Sialate O-Acetylesterase in monoclonal antibody formulations.</a> Journal of Pharmaceutical Sciences. 110 (12), 3866-3873 (2021).</li><li>Zhang, S., Xiao, H., Molden, R., Qiu, H., Li, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rapid+polysorbate+80+degradation+by+liver+carboxylesterase+in+a+monoclonal+antibody+formulated+drug+substance+at+early+stage+development.">Rapid polysorbate 80 degradation by liver carboxylesterase in a monoclonal antibody formulated drug substance at early stage development.</a> Journal of Pharmaceutical Sciences. 109 (11), 3300-3307 (2020).</li><li>Gunawan, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comparison+of+platform+host+cell+protein+ELISA+to+process-specific+host+cell+protein+ELISA.">Comparison of platform host cell protein ELISA to process-specific host cell protein ELISA.</a> Biotechnology and Bioengineering. 115 (2), 382-389 (2018).</li><li>Chen, I. H., Xiao, H., Daly, T., Li, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Improved+host+cell+protein+analysis+in+monoclonal+antibody+products+through+molecular+weight+cutoff+enrichment.">Improved host cell protein analysis in monoclonal antibody products through molecular weight cutoff enrichment.</a> Analytical Chemistry. 92 (5), 3751-3757 (2020).</li><li>Chen, I. H., Xiao, H., Li, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Improved+host+cell+protein+analysis+in+monoclonal+antibody+products+through+ProteoMiner.">Improved host cell protein analysis in monoclonal antibody products through ProteoMiner.</a> Analytical Biochemistry. 610, 113972 (2020).</li><li>Doneanu, C. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enhanced+detection+of+low-abundance+host+cell+protein+impurities+in+high-purity+monoclonal+antibodies+down+to+1+ppm+using+ion+mobility+mass+spectrometry+coupled+with+multidimensional+liquid+chromatography.">Enhanced detection of low-abundance host cell protein impurities in high-purity monoclonal antibodies down to 1 ppm using ion mobility mass spectrometry coupled with multidimensional liquid chromatography.</a> Analytical Chemistry. 87 (20), 10283-10291 (2015).</li><li>Huang, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+Novel+sample+preparation+for+shotgun+proteomics+characterization+of+HCPs+in+antibodies.">A Novel sample preparation for shotgun proteomics characterization of HCPs in antibodies.</a> Analytical Chemistry. 89 (10), 5436-5444 (2017).</li><li>Johnson, R. O., Greer, T., Cejkov, M., Zheng, X., Li, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Combination+of+FAIMS,+Protein+A+depletion,+and+native+digest+conditions+enables+deep+proteomic+profiling+of+host+cell+proteins+in+monoclonal+antibodies.">Combination of FAIMS, Protein A depletion, and native digest conditions enables deep proteomic profiling of host cell proteins in monoclonal antibodies.</a> Analytical Chemistry. 92 (15), 10478-10484 (2020).</li><li>Kreimer, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Host+cell+protein+profiling+by+targeted+and+untargeted+analysis+of+data+independent+acquisition+mass+spectrometry+data+with+parallel+reaction+monitoring+verification.">Host cell protein profiling by targeted and untargeted analysis of data independent acquisition mass spectrometry data with parallel reaction monitoring verification.</a> Analytical Chemistry. 89 (10), 5294-5302 (2017).</li><li>Madsen, J. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Toward+the+complete+characterization+of+host+cell+proteins+in+biotherapeutics+via+affinity+depletions,+LC-MS/MS,+and+multivariate+analysis.">Toward the complete characterization of host cell proteins in biotherapeutics via affinity depletions, LC-MS/MS, and multivariate analysis.</a> MAbs. 7 (6), 1128-1137 (2015).</li><li>Nie, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Simple+and+sensitive+method+for+deep+profiling+of+host+cell+proteins+in+therapeutic+antibodies+by+combining+ultra-low+trypsin+concentration+digestion,+long+chromatographic+gradients,+and+boxcar+mass+spectrometry+acquisition.">Simple and sensitive method for deep profiling of host cell proteins in therapeutic antibodies by combining ultra-low trypsin concentration digestion, long chromatographic gradients, and boxcar mass spectrometry acquisition.</a> Analytical Chemistry. 93 (10), 4383-4390 (2021).</li><li>Yang, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Versatile+LC-MS-Based+workflow+with+robust+0.1+ppm+sensitivity+for+identifying+residual+HCPs+in+biotherapeutic+products.">Versatile LC-MS-Based workflow with robust 0.1 ppm sensitivity for identifying residual HCPs in biotherapeutic products.</a> Analytical Chemistry. 94 (2), 723-731 (2022).</li><li>Zhang, Q. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Comprehensive+tracking+of+host+cell+proteins+during+monoclonal+antibody+purifications+using+mass+spectrometry.">Comprehensive tracking of host cell proteins during monoclonal antibody purifications using mass spectrometry.</a> MAbs. 6 (3), 659-670 (2014).</li><li>Zhang, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Putative+phospholipase+B-Like+2+is+not+responsible+for+polysorbate+degradation+in+monoclonal+antibody+drug+products.">Putative phospholipase B-Like 2 is not responsible for polysorbate degradation in monoclonal antibody drug products.</a> Journal of Pharmaceutical Sciences. 109 (9), 2710-2718 (2020).</li><li>Zhang, J., He, J., Smith, K. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Fatty+acids+can+induce+the+formation+of+proteinaceous+particles+in+monoclonal+antibody+formulations.">Fatty acids can induce the formation of proteinaceous particles in monoclonal antibody formulations.</a> Journal of Pharmaceutical Sciences. 111 (3), 655-662 (2022).</li><li>Uniprot1. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> , (2023).</li><li>Uniprot2. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> , (2023).</li></ol>

The authors have no competing financial interests.

There are two versions of commercially available protein enrichment beads: one with a smaller capacity and the other with a larger capacity (see Table of Materials). Both versions of the enrichment beads contain ten preps in the package. The manufacturer's instructions suggest that each prep from the small capacity kit can be used to enrich 10 mg of total protein. However, for optimal performance of host cell protein (HCP) enrichment from DS, each prep is good for five DS samples. Therefore, each kit can...

Host cell proteins (HCPs) are impurities that are released from the cell culture of the host organism and co-purified with monoclonal antibody (mAb)1,2,3,4. Trace levels of HCPs can negatively impact the quality of the drug product5,6,7,8,9,10,11,12,13,14,15, and therefore, a sensitive HCP analysis method is desired to detect HCPs in sub-ppm to ppm levels.
Orthogonal methods can be applied to detect HCPs in low abundance. Enzyme-linked immunosorbent assay (ELISA) is generally used to quantitate overall HCPs, and it can also detect and quantitate individual HCPs if the corresponding antibodies are available16. However, the production of HCP-specific antibodies is time-consuming and labor-intensive. In contrast, liquid chromatography coupled with mass spectrometry (LC-MS) can provide comprehensive information about individual HCPs in mAb drug products and is widely applied for HCP identification4,7,9,10,12,13,14,15,17,18,19,20,21,22,23,24,25,26,27.
Several methods have been developed to detect HCPs with LC-MS/MS, including limited digestion20, filtration17, Protein A deletion21, immunoprecipitation (IP), and ProteoMiner enrichment (PM)18. Most methods aim to reduce the amount of mAb and enrich HCPs prior to LC-MS/MS analysis, thereby decreasing the dynamic range between mAb peptides and HCP peptides. This protocol presents a proteomic sample enrichment method that combines ProteoMiner technology and limited digestion (PMLD)28. The ProteoMiner enrichment principle involves using commercially available proteome enrichment beads containing a diverse library of combinatorial peptide ligands. These ligands specifically bind to proteins on antibody-drug products, allowing for the removal of excess molecules while concentrating low-abundance host cell proteins (HCPs) on their respective affinity ligands. On the other hand, the principle of limited digestion involves using a low concentration of trypsin. This concentration is sufficient to digest low-abundance HCPs but not enough to digest all antibody drug products. This approach enables the recovery and enrichment of digested HCP peptides from the solution.
Compared to filtration methods, the PMLD technique is not limited by the size of the detected HCPs17. Protein A deletion methods are specific to detecting HCPs associated with antibodies21, while immunoprecipitation is restricted to predefined HCPs from a particular cell line (such as the Chinese Hamster Ovary (CHO) cell line), where an anti-HCP antibody was generated4. In contrast, PMLD can be applied to detect HCPs from any drug modules and host cell proteins co-purified with drug products from various cell lines. Additionally, PMLD exhibits better sensitivity compared to the mentioned methods17,18,20,21,24.
This approach can enrich the HCP concentration by 7000-fold and lower the detection limit to 0.002 ppm28. The experimental setup is illustrated in Figure 1.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>16 G, Metal Hub Needle, 2 in, point style 3</td>
			<td>Hamilton</td>
			<td>91016</td>
			<td></td>
		</tr>
		<tr>
			<td>Acclaim PepMap 100 C18 trap column (20 cm &#215; 0.075 mm)</td>
			<td>Thermo Fisher</td>
			<td>164535</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetonitrile</td>
			<td>Fisher-Scientific</td>
			<td>A955</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetonitrile with 0.1% Formic Acid (v/v), Optima LC/MS Grade&#160;</td>
			<td>Fisher-Scientific</td>
			<td>LS120-4</td>
			<td></td>
		</tr>
		<tr>
			<td>Amicon Ultra-0.5 Centrifugal Filter Unit</td>
			<td>Millipore Sigma</td>
			<td>UFC5010</td>
			<td></td>
		</tr>
		<tr>
			<td>C18 analytical column (0.075 mm &#215; 1.7 &#956;m &#215; 30 cm, 100 &#197;)</td>
			<td>CoAnn Technologies</td>
			<td>HEB07503001718I</td>
			<td></td>
		</tr>
		<tr>
			<td>Centrifuge 5424</td>
			<td>Eppendorf</td>
			<td>5405000646</td>
			<td></td>
		</tr>
		<tr>
			<td>Dithiothreitol (DTT)&#160;</td>
			<td>Thermo Fisher</td>
			<td>A39255</td>
			<td></td>
		</tr>
		<tr>
			<td>Frit for SPE cartridges, 9.5 mm, 3 mL, 100/pk</td>
			<td>Agilent</td>
			<td>12131020</td>
			<td></td>
		</tr>
		<tr>
			<td>GL-Tip GC</td>
			<td>GL Sciences Inc&#160;&#160;</td>
			<td>7820-11201</td>
			<td></td>
		</tr>
		<tr>
			<td>in-house mAb</td>
			<td>Regeneron</td>
			<td></td>
			<td>concentration 200 mg/mL</td>
		</tr>
		<tr>
			<td>Iodoacetamide (30 x 9.3 mg)</td>
			<td>Thermo Fisher</td>
			<td>A39271</td>
			<td></td>
		</tr>
		<tr>
			<td>Isopropanol</td>
			<td>Fisher-Scientific</td>
			<td>149320025</td>
			<td></td>
		</tr>
		<tr>
			<td>L-Histidine</td>
			<td>Sigma Aldrich</td>
			<td>H6034</td>
			<td></td>
		</tr>
		<tr>
			<td>L-Histidine monohydrochloride monohydrate</td>
			<td>Sigma Aldrich</td>
			<td>53370</td>
			<td></td>
		</tr>
		<tr>
			<td>Methanol</td>
			<td>Fisher-Scientific</td>
			<td>A456-4&#160;</td>
			<td></td>
		</tr>
		<tr>
			<td>Milli-Q</td>
			<td>Millpore</td>
			<td>30035</td>
			<td></td>
		</tr>
		<tr>
			<td>NanoDrop 2000</td>
			<td>Thermo Scientific</td>
			<td>ND-2000</td>
			<td></td>
		</tr>
		<tr>
			<td>Orbitrap Exploris 480</td>
			<td>Thermo Fisher</td>
			<td>BRE725539</td>
			<td></td>
		</tr>
		<tr>
			<td>Protein LoBind Tube 0.5 mL</td>
			<td>Eppendorf (VWR)</td>
			<td>22431064</td>
			<td></td>
		</tr>
		<tr>
			<td>Protein LoBind Tube 2.0 mL</td>
			<td>Eppendorf (VWR)</td>
			<td>22431102</td>
			<td></td>
		</tr>
		<tr>
			<td>Proteome Discoverer software 2.4</td>
			<td>Thermo Scientific</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>ProteoMiner Protein Enrichment Large-Capacity Kit</td>
			<td>Bio-Rad</td>
			<td>1633007</td>
			<td></td>
		</tr>
		<tr>
			<td>ProteoMiner Protein Enrichment Small-Capacity Kit</td>
			<td>Bio-Rad</td>
			<td>1633006</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium deoxycholate (SDC)</td>
			<td>Sigma Aldrich</td>
			<td>D6750</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium lauroyl sarcosinate (SLS)&#160;</td>
			<td>Sigma Aldrich</td>
			<td>L5777</td>
			<td></td>
		</tr>
		<tr>
			<td>SpeedVac</td>
			<td>Labconco</td>
			<td>7970010</td>
			<td></td>
		</tr>
		<tr>
			<td>Thermomixer R</td>
			<td>Eppendorf</td>
			<td>22670107</td>
			<td></td>
		</tr>
		<tr>
			<td>Trifluoracetic acid (TFA)</td>
			<td>Fisher-Scientific</td>
			<td>28904</td>
			<td></td>
		</tr>
		<tr>
			<td>Trypsin (Sequencing Grade Modified)&#160; (5 x 20 ug)</td>
			<td>Promega</td>
			<td>V5111</td>
			<td></td>
		</tr>
		<tr>
			<td>Tube Revolver Rotator</td>
			<td>Thermo Fisher</td>
			<td>88881001</td>
			<td></td>
		</tr>
		<tr>
			<td>UltiMate 3000 RSLC nano system</td>
			<td>Thermo Fisher</td>
			<td>ULTIM3000RSLCNANO</td>
			<td></td>
		</tr>
		<tr>
			<td>UltraPure 1 M Tris-HCl pH 8.0</td>
			<td>Thermo Fisher</td>
			<td>15568-025</td>
			<td></td>
		</tr>
		<tr>
			<td>Vortex Genie 2</td>
			<td>VWR</td>
			<td>102091-234</td>
			<td></td>
		</tr>
		<tr>
			<td>Water with 0.1% Formic Acid (v/v), Optima LC/MS Grade&#160;</td>
			<td>Fisher-Scientific</td>
			<td>LS118-4&#160;</td>
			<td></td>
		</tr>
	</tbody>
</table>

host cell protein analysis using enrichment beads coupled with limited digestion

Host cell proteins (HCPs) are impurities that can adversely affect therapeutic proteins, even in small quantities. To evaluate the potential risks associated with drug products, methods have been developed to identify low-abundance HCPs. A crucial approach for developing a sensitive HCP detection method involves enriching HCPs while simultaneously removing monoclonal antibodies (mAbs) before analysis, utilizing liquid chromatography-mass spectrometry (LC-MS).
This protocol offers detailed instructions for enriching host cell proteins using commercially available proteome enrichment beads. These beads contain a diverse library of hexapeptide ligands with specific affinities for different proteins. The protocol also incorporates limited digestion and subsequent peptide detection using nano LC-MS/MS. By employing these techniques, HCPs with low abundance can be enriched over 7000-fold, resulting in an impressive detection limit as low as 0.002 ppm. Significantly, this protocol enables the detection of 850 HCPs with a high level of confidence using a NIST mAb. Moreover, it is designed to be user-friendly and includes a video demonstration to assist with its implementation. By following these steps, researchers can effectively enrich and detect HCPs, enhancing the sensitivity and accuracy of risk assessment for drug products.

Author Spotlight: Detecting Low-Abundant Host Cell Proteins in Drug Products Using Enrichment Beads and Limited Digestion 

Host Cell Protein Analysis using Enrichment Beads Coupled with Limited Digestion

We have developed a highly sensitive method to detect those low-abundant host cell protein from the drug product using the proteome enrichment beads. This approach help us to find the root cause and the risk associated with the drug product. There are multiple ways to improve the detection limit of HCP analysis, the untargeted method including but not limited to protein A depletion, the limited digestion, the molecular weight cutoff, the immunoprecipitation.The targeted way to detect the host cell protein, including liquid chromatography, multiple reaction monitoring, and the non-liquid chromatography parallel reaction monitoring. The major challenge associate with these HCP analysis is the significant dynamic range between antibody drug and host cell proteins. So most method aim to reduce the amount of antibody and the enrich HCP before LCMS analysis to decrease the dynamic range between antibody peptides and HCP peptides.So ProteoMiner technology and the limited digestion protocol significantly improve the detection limit of HCP analysis compared to other methods. It's non-biased compared to immunoprecipitation and can be applied to different drug module compared to protein A depletion method. This protocol is also simple and straightforward.So ProteoMiner technology and limited digestion protocol help us to identify several HCPs that degrade polysorbate and the fragment antibody drug. In combination with the nano LCMPRM method, the enrichment method can also provide quantitative results to find the biological relevant concentration of problematic host cell proteins.

This protocol presented a sample preparation workflow, termed protein enrichment coupled with limited digestion (PMLD), for the analysis of host cell proteins (HCPs) in a monoclonal antibody (mAb) sample. Figure 1 illustrates the step-by-step procedure of PMLD. The researchers compared the results of HCP analysis using direct digestion (shown in the top panel of Figure 2) and PMLD (shown in the bottom panel of Figure 2). The Total I...

Watch this Scientific Journal Video about Detecting Low-Abundant Host Cell Proteins in Drug Products Using Enrichment Beads and Limited Digestion at JoVE.com

A protocol is presented for enriching host cell proteins (HCPs) from drug products (DP) and detecting peptides using proteome enrichment beads. The method is demonstrated using an in-house manufactured monoclonal antibody (mAb) drug substance (DS), which is a well-characterized reference material for evaluating and comparing different methods in terms of performance.

Host cell proteins (HCPs) are impurities that can adversely affect therapeutic proteins, even in small quantities. To evaluate the potential risks ...

host-cell-protein-analysis-using-enrichment-beads-coupled-with

Research

JoVE Journal

Chemistry

1.5K visualizações.  Regeneron Pharmaceuticals Inc.. Desenvolvemos um método altamente sensível para detectar essas proteínas de células hospedeiras pouco abundantes a partir do produto farmacêutico usando as esferas de enriquecimento de proteoma. Esta abordagem ajuda-nos a encontrar a causa raiz e o risco associado ao produto farmacêutico. Existem várias maneiras de melhorar o limite de detecção da análise de HCP, o método não direcionado, incluindo, mas não limitado a, depleção de proteína A, a digestão limitada, o corte de p...

Vídeo: Autor em destaque: Detecção de proteínas de células hospedeiras de baixa abundância em medicamentos usando grânulos de enriquecimento e digestão limitada 